Therefore, an estimate of individual effectiveness will provide a better idea of how TB-HIV co-infected patients with a preserved immunity (CD4+ T count above 350cells/mm3) respond to cART under programmatic conditions [15]. Here, CD4 is linked to tuberculosis.